Widow halfway through ‘healing' 5,000-mile British coastline charity challenge
A widow walking 5,000 miles around the British coastline in memory of her late wife said she is 'enjoying living in the moment' as she passed the halfway mark of her challenge.
Tracey Howe, a retired professor from Glasgow, has faced various challenges, including injuries and weather conditions, while covering the west and south coast of the country.
Ms Howe, 61, is also giving out 5,000 crocheted hearts along her walk to strangers to remind people of those they have loved and lost.
The mother-of-two started her coastline challenge from Glasgow last November and aims to finish there on October 31 2025.
Ms Howe, who lost her wife Angela of 37 years to blood cancer in September 2023, said the walking expedition has been an opportunity for her to process her grief.
'When I started, it was just a year since Angela had died, and I was really immersed in my grief,' Ms Howe told the PA news agency.
'I was crying a lot every day and shouting at the weather and battling the elements, because it was winter time.
'Sometimes I would call on Angela to give me a hand, to give me a push up the hill.'
Ms Howe, who is walking an average of 20 miles per day six days a week, hopes to raise £100,000, which will be split between five charities – Beatson Cancer Charity, Marie Curie, Brainstrust, Breast Cancer Now and CoppaFeel.
She said she has been encouraged by the support she has received so far, including from Olympian Tom Daley, who crocheted several pink hearts for her to 'encourage more people to talk about their grief'.
Ms Howe lost her wife Angela to blood cancer, which she developed after recovering from an operation removing a benign tumour.
'I've spent a lot of time talking in my head trying to get a sense of what happened,' she said.
'It was a long, long journey and very complicated with different things.
'We never really had time to process the brain tumour before we were into blood cancer and one thing and another.
'There's a lot of processing to do, and so I feel like I've had space and time to do that, because 99% of the time I'm on my own.'
Ms Howe, who has already covered 2,500 miles, hitting a number of significant landmarks including Land's End and Lizard Point, said she has learned to enjoy living in the moment.
'What I've learned is that I am now enjoying living in the moment, soaking everything up. It's easy to live for tomorrow but we need to make the most of each day,' she said
'I'm much more relaxed about changing plans if things go wrong or not to plan.
'The worst has happened so everything is now more in perspective.
'I encourage everyone who is grieving to take the first step out into the world – it's truly a healing place.'
Ms Howe is currently walking through Kent and plans to spend the summer walking up the east coast of the UK in Norfolk and Yorkshire before heading to Scotland for the last leg of her journey.
To learn more about Ms Howe's coastal challenge you can visit her fundraising page at: https://www.givewheel.com/fundraising/4117/traceystrek/
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Churchill documents reveal D-Day landings boosted by import of ‘wonder drug' from America
Newly unearthed documents have revealed that the D-Day landings received a boost from the import of a "wonder drug" from America. Despite its discovery in London in 1928 by Sir Alexander Fleming, large-scale production of the antibiotic penicillin had struggled to take hold in Britain. Attempts to produce substantial quantities of medicine from the bacteria-killing mould had not been achieved by the start of the Second World War. Then prime minister Sir Winston Churchill became increasingly frustrated that Britain had not been able to produce enough penicillin in the preparations for the Normandy landings in 1944. Official papers released by the National Archive – containing handwritten notes by Sir Winston – highlight efforts to boost quantities of the antibiotic, with Britain eventually forced to import it from America. The documents were released ahead of the 81st anniversary of D-Day, the Allied invasion of Normandy on June 6, 1944. In one report on February 19, after the issue had been raised in the House of Commons, Sir Winston scrawled in red ink on a Ministry of Supply report noting the Americans were producing greater quantities: 'I am sorry we can't produce more.' On another paper, he complained: 'Your report on penicillin showing that we are only to get about one tenth of the expected output this year, is very disappointing.' Elsewhere in the same file he instructs: 'Let me have proposals for a more abundant supply from Great Britain.' With preparations for D-Day ramped up, efforts to deliver enough American-made penicillin for frontline military personnel soon became a matter of urgency. Decisions needed to be made on the quantities of antibiotic imported, how much to administer to individual patients, and how to get medical staff trained in time. Most British doctors did not know how to issue penicillin – until this point, doctors had nothing available to treat infections like pneumonia and many people died of blood poisoning after minor injuries because no drug existed that could cure them. Early in January 1944, Prof FR Fraser, the Ministry of Health's adviser on the organisation of wartime hospitals, wrote that 50,000-100,000 wounded could be expected from the Second Front. He proposed the Emergency Medical Services might need as many as five billion units of penicillin per month for this. Further documents show discussions on whether the antibiotic should be supplied as calcium or sodium salts, or in tablet form. Ultimately, it was agreed powdered calcium salts would be issued for superficial wounds and sodium salts for use in deep wounds. On May 24 1944, less than a fortnight before D-Day, Prof Fraser reported: 'Sufficient supplies of penicillin are now available for the treatment of battle casualties in EMS hospitals, but not for ordinary civilian patients.' Plans were made for casualties from the frontline in France to be brought back to coastal hospitals in Britain for treatment. A week before D-Day, on May 30 1944, hospitals were instructed to treat battlefield patients en route: 'In an endeavour to prevent the development of gas gangrene and sepsis in wounds the War Office have arranged for the treatment of selected cases by penicillin to be commenced as soon after injury as possible.' Injections of penicillin were to be given to them at intervals of not more than five hours and patients would be wearing a yellow label with the letters 'PEN'. The time and size of penicillin doses should be written on it, they were told. Dr Jessamy Carlson, modern records specialist at the National Archives, said: 'File MH 76/184 gives a glimpse into the extraordinary levels of preparation undertaken in advance of the D-Day landings. 'Only six weeks before, penicillin is just reaching our shores in quantities which will allow it to play a major role in improving the outcomes for service personnel wounded in action.' As Allied forces made inroads into Europe, restrictions on the use of penicillin for civilians began to relax, but only in special cases. In July 1944, Ronald Christie, professor of medicine, wrote to Prof Fraser to tell him: 'The War Office approves of American penicillin being used for medical conditions in service patients and for air raid casualties among civilians.' On the home front, demand for the new 'wonder' drug began to increase, according the National Archives. It was decided that penicillin for civilians should only be supplied to larger hospitals where the staff had been properly trained to administer it. Only in 1946 did it become fully available for the general public.
Yahoo
a day ago
- Yahoo
D-Day landings boosted by import of ‘wonder drug' to Britain, archives reveal
The D-Day landings were boosted by the import from America of a 'wonder drug', unearthed documents reveal. Production of the antibiotic penicillin had struggled to take hold at a large scale in Britain, despite being discovered in 1928 in London by Sir Alexander Fleming. Attempts to produce substantial quantities of medicine from the bacteria-killing mould had not been achieved by the start of the Second World War. Then prime minister Sir Winston Churchill became increasingly frustrated that Britain had not been able to produce enough penicillin in the preparations for the Normandy landings in 1944. Official papers released by the National Archive – containing handwritten notes by Sir Winston – highlight efforts to boost quantities of the antibiotic, with Britain eventually forced to import it from America. The documents were released ahead of the 81st anniversary of D-Day, the Allied invasion of Normandy on June 6, 1944. In one report on February 19, after the issue had been raised in the House of Commons, Sir Winston scrawled in red ink on a Ministry of Supply report noting the Americans were producing greater quantities: 'I am sorry we can't produce more.' On another paper, he complained: 'Your report on penicillin showing that we are only to get about one tenth of the expected output this year, is very disappointing.' Elsewhere in the same file he instructs: 'Let me have proposals for a more abundant supply from Great Britain.' With preparations for D-Day ramped up, efforts to deliver enough American-made penicillin for frontline military personnel soon became a matter of urgency. Decisions needed to be made on the quantities of antibiotic imported, how much to administer to individual patients, and how to get medical staff trained in time. Most British doctors did not know how to issue penicillin – until this point, doctors had nothing available to treat infections like pneumonia and many people died of blood poisoning after minor injuries because no drug existed that could cure them. Early in January 1944, Prof FR Fraser, the Ministry of Health's adviser on the organisation of wartime hospitals, wrote that 50,000-100,000 wounded could be expected from the Second Front. He proposed the Emergency Medical Services might need as many as five billion units of penicillin per month for this. Further documents show discussions on whether the antibiotic should be supplied as calcium or sodium salts, or in tablet form. Ultimately, it was agreed powdered calcium salts would be issued for superficial wounds and sodium salts for use in deep wounds. On May 24 1944, less than a fortnight before D-Day, Prof Fraser reported: 'Sufficient supplies of penicillin are now available for the treatment of battle casualties in EMS hospitals, but not for ordinary civilian patients.' Plans were made for casualties from the frontline in France to be brought back to coastal hospitals in Britain for treatment. A week before D-Day, on May 30 1944, hospitals were instructed to treat battlefield patients en route: 'In an endeavour to prevent the development of gas gangrene and sepsis in wounds the War Office have arranged for the treatment of selected cases by penicillin to be commenced as soon after injury as possible.' Injections of penicillin were to be given to them at intervals of not more than five hours and patients would be wearing a yellow label with the letters 'PEN'. The time and size of penicillin doses should be written on it, they were told. Dr Jessamy Carlson, modern records specialist at the National Archives, said: 'File MH 76/184 gives a glimpse into the extraordinary levels of preparation undertaken in advance of the D-Day landings. 'Only six weeks before, penicillin is just reaching our shores in quantities which will allow it to play a major role in improving the outcomes for service personnel wounded in action.' As Allied forces made inroads into Europe, restrictions on the use of penicillin for civilians began to relax, but only in special cases. In July 1944, Ronald Christie, professor of medicine, wrote to Prof Fraser to tell him: 'The War Office approves of American penicillin being used for medical conditions in service patients and for air raid casualties among civilians.' On the home front, demand for the new 'wonder' drug began to increase, according the National Archives. It was decided that penicillin for civilians should only be supplied to larger hospitals where the staff had been properly trained to administer it. Only in 1946 did it become fully available for the general public.
Forbes
a day ago
- Forbes
Smart Healthcare: The AI Revolution Empowering The Frontline
The use and integration of AI in medicine is driving a quiet revolution in healthcare Speaking at the recent SXSW London festival, former British Prime Minister Sir Tony Blair said the UK should embrace a future of AI doctors and nurses, or risk being left behind in the biggest upheaval since the Industrial Revolution. He went on to say that fears about artificial intelligence should be outweighed by the 'absolutely transformative' impact it could have on public services like healthcare and education by saving time and money - 'When I stand back and look at what AI is doing, I think we're in the foothills of the most transformative revolution since the Industrial Revolution of the 19th century'. This bold claim by the former Prime Minister follows hot on the heels of news coming out of Saudi Arabia, regarding the world's first AI-powered doctor's clinic, where Shanghai-based Synyi AI's "Dr. Hua" is already diagnosing and prescribing treatment for respiratory ailments. It paints a vivid picture of a future where artificial intelligence autonomously cares for our health in a way that was considered science fiction only a few years ago. But while such developments are thought provoking, I firmly believe that the true, impactful role of AI in the short to medium term is not to replace human clinicians, but to powerfully augment them. There are compelling reasons for this perspective, extending beyond the obvious concern of potential error and the severe consequences should one occur in a medical context. Equally important is the intricate ecosystem of healthcare itself. Clinicians are not merely service providers; they are key stakeholders deeply invested in their roles, particularly in the most critical and decision-intensive aspects of patient care. They will legitimately cite safety concerns when contemplating the ceding of such control, but it would be naïve to ignore the financial incentives and professional autonomy that also shape their approach. Therefore, the integration of AI in healthcare has, quite rightly, begun in auxiliary roles. We've already seen AI excel in tasks such as note-keeping, drafting letters and managing paperwork – administrative burdens that often detract from direct patient interaction. This evolution will steadily progress to passive monitoring, for instance, checking prescription drug dosages, identifying potential interactions and flagging contraindications. From there, AI will transition into more active advisory capacities, suggesting diagnoses, recommending follow-up investigations, and outlining possible treatment options. Crucially, however, the final, nuanced decision will remain firmly in the hands of a highly trained human expert. This measured arc of AI integration presents a profound "win-win-win" scenario. For physicians, it offers a pathway to significantly increased job satisfaction and reduced burnout. I am yet to meet a physician who genuinely enjoys the endless paperwork; many would willingly forgo a portion of their salary to alleviate this burden. By offloading these tasks to AI, doctors can reclaim precious time, focusing their energy on what truly matters: direct patient engagement and complex problem-solving. Patients too stand to benefit immensely. Imagine a consultation where your doctor makes genuine eye contact, actively listens and engages in a conversation, rather than constantly typing or staring at their screen. This enhanced human connection, facilitated by AI managing the background administrative load, promises a more empathetic and effective healthcare experience. For healthcare systems, the advantages are equally compelling. Reimbursement often hinges on the quality and accuracy of medical notes, an area where AI can deliver substantial improvements. By enhancing the precision and completeness of documentation, AI can streamline processes and bolster financial stability. Slowly but surely, however, the conversation will shift from augmentation to replacement. This transition is likely to occur first in less critical areas, such as routine follow-up visits or standard checks. More significantly, it may take hold in resource-constrained environments where the alternative to AI is not a highly skilled human professional, but rather, nothing at all. Some industry observers are worried that this could lead to a two-tiered healthcare system, where human physicians attend to the affluent, while the less privileged are left with an inferior, AI-driven substitute for the care they truly need. This, they argue, will exacerbate existing health inequalities. Personally, I believe they are right to worry about AI exacerbating existing health inequalities, but I think they might have the story backwards. As AI continues its relentless improvement, it is plausible that at some point, perhaps sooner than many anticipate – it will surpass human physicians across all dimensions, including the delicate art of bedside manner and empathy. When this happens, perhaps the opposite scenario will unfold: the affluent world will be treated by the superior Dr. AI, while the less privileged may find themselves priced out of access to these expensive, patent-protected AI systems, and instead have to contend with the comparatively inferior human alternative. It's a provocative thought, but one we must seriously consider as we navigate the extraordinary potential and profound ethical implications of AI in healthcare. Professor Nicos Savva is a Professor of Management Science at London Business School and an expert in data science, using it to solve operational problems and help large organisations develop data-science capabilities. His research at LBS focuses on healthcare management, including hospital operations, regional organization of care, assessing performance, measuring health inequity, and innovation. Professor Savva's work has appeared in leading journals such as Management Science, Manufacturing & Service Operations Management and Nature Biotechnology.
